Shapiro RE, Hochstetler HM, Dennehy EB, et al. - In the acute treatment of migraine attacks in patients with cardiovascular risk factors (CVRFs), researchers tested the safety and effectiveness of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist. The study participants were adults who used lasmiditan 50, 100, or 200 mg to treat a single migraine attack. No statistical difference was found in lasmiditan effectiveness or the frequency of likely CV treatment-emergent adverse events when analyzed by the presence of CVRFs. Although the analysis is limited by a single-migraine-attack design, the lack of differences in effectiveness and safety with increasing numbers of CVRFs shows that lasmiditan may be considered in the treatment algorithm for CVRF patients. In order to evaluate long-term efficacy and safety, future studies are required.